<link rel="stylesheet" href="/res/styles.39be4579664c3a48.css">
Artículo

Assessment of Immune Related Rheumatological Adverse Events in A Monovalent Oncology Center in Argentina

Sabio Collado, María Victoria Icon; Gandur, María Natalia ; Zerga, Marta Elisa ; Cugliari, María Silvana ; Castro, Mónica ; Cuartero, Viviana ; Cáceres, Valeria ; Serrano, Laura Marcela ; Casas Parera, Ignacio Faustino ; Cinat, Gabriela ; Ranuncolo, Stella Maris Icon

Otros responsables

Fecha

12/2025

Editorial

CME Live Publishes Open Access

Revista

CME Journal of Clinical Case Report

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

eISSN

3067-7998

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Background: Immune checkpoint inhibitors (ICIs) have changed the oncology patients´ outcome. They are being used inan increasingly number of different cancers. Consequently, there is enhanced ICIs-associated-toxicity, named immunerelated-adverse-events. Objectives: To define the Immune-related-Rheumatologic-Adverse-Events (IrRAEs) in ICIs treatedoncological patients, determining the oncological treatment continuity following their development. To investigatewhether pre-existing rheumatologic diseases (PRD).explained the ICI-treatment initiation failure. Material and Methods:This descriptive-retrospective study Included 42 oncology patients, initiating or already undergoing ICI treatment, referredto the Rheumatology Department during 2019-2022. Results: 40/159 (25%) patients that received ICI treatment at theRoffo Oncology Institute, were evaluated by the Rheumatology Department. 16/40 experienced IrRAEs [IrRAEs` treatment:5/16 received non-steroidal anti-infammatory drugs, 11/16 corticosteroids (5/11 required additionally Disease-ModifyingAntirheumatic Drugs (DMARDs)]. The IrRAEs treatment outcome was: complete response (9/16), partial response (2/16) andno response (5/16). As a consequence 7/16 patients (44%) continued the ICI therapy, 3/16 (19%) experienced a temporarysuspension and 6/16 (37%) a permanent discontinuation. Two patients didn´t iniciate ICIs due to PRD. Conclusions: 25%of the total ICI treated patients developed rheumatologyc symptoms. The IrRAEs were the cause of them in 16/40 patients.Therefore 10% (16/159) of the total ICI treated patients developed IrRAEs, being most of them mild to moderate. Only onepatient, suffering myositis, experienced a severe life-threatening IrRAE. The patients´ evaluation at the time they startedthe ICI therapy allowed the PRD diagnosis and to monitore exacerbations. Half of the patients who developed IrRAEs werecapable to continue their ICI treatment.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa